Amyotrophic lateral sclerosis research program

Ended Awarded Last action

Contract number
HT942525F0091
Awardee
Awarding agency
Obligated
$198,840

Award facts

Opportunity
Contract value 94% obligated
$212,554.34 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21702, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00002 -$13,714
Supplemental Agreement for work within scope P00001 $31,827
Original award $180,728

About this award

The Defense Health Agency issued a $212,554.34 delivery order to Leidos, Inc. on May 1, 2025, for the Amyotrophic Lateral Sclerosis Research Program, with performance completion by April 30, 2026.

Place of performance is Frederick, MD. The order is priced on a cost-plus-fixed-fee basis. Leidos, Inc. operates through its Leidos Services Operating Segment Division.

Quick answers

Who was awarded contract HT942525F0091?

HT942525F0091 was awarded to Leidos, Inc. by Defense Health Agency (Department of Defense) on May 1, 2025.

How much is contract HT942525F0091 worth?

The government has obligated $198,840 on HT942525F0091. Its current value, with exercised options, is $212,554.

Is contract HT942525F0091 an order under another contract?

Yes. HT942525F0091 is a delivery order under HT942523D0002, an indefinite delivery contract.

Was contract HT942525F0091 competed?

The extent of competition for HT942525F0091 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award